All Posts Tagged With: "Pharmaceutical Patents"
A Law Firm’s View on Pharmaceutical Patents
Pharmaceutical Patents - Ropes & Gray LLP
Excerpt: Patent protection is the foundation of pharmaceutical innovation. Without strong, effective patents, pharmaceutical companies would be unable to recoup the enormous cost of drug development and invest in important new research projects. Understandably, many leading companies in the pharmaceutical industry rely on the Intellectual Property Group to secure and enforce the patents that ensure their financial and strategic success.
The Risks of Violating Pharmaceutical Patents
Cipro and the Risks of Violating Pharmaceutical Patents - NCPA, November 2001
Excerpt: When the threat of anthrax became a widespread concern, the Canadian government said it had serious doubts that Bayer, the owner of the patent for the anti-anthrax drug Cipro, could meet Canadian needs. Canada ignored the patent and ordered generic copies. In the United States, Sen. Charles Schumer expressed the same concerns and proposed that the U.S. government do the same. After Bayer said it could meet the needs of both nations, and after other drugs that are effective against anthrax were identified, Canada reversed its decision, and the issue was dropped in the United States for the time being.
Pharmaceutical Patents PDF from Innovation.org
Pharmaceutical Patents (PDF) - Innovation.org
Excerpt: Patent protection in the United States gives inventors the exclusive right to sell an invention for up to 20 years before others may copy and sell it. However, the effective patent life, which only begins to run when the patent is granted and the invention can be marketed, is closer to 18 ½ years. For pharmaceuticals, the effective patent life is actually closer to 11 or 12 years since federal law requires a company to test its product for safety and efficacy and secure regulatory approval before marketing it, a process that can take years.
SSRN on Pharmaceutical Patents
Navigating the Anticommons for Pharmaceutical Patents: Steady the Course on Hatch-Waxman - SSRN, March 2004
Excerpt: Much recent work has trumpeted the so-called problem of the anticommons in the patent field, especially in connection with medical tools. That conclusion rests on a mistaken comparison of government bureaucrats who lack strong institutional incentives to issue needed permits, and does not carry over to entrepreneurs who only make money by making deals. The analysis also wrongfully assumes that additional patents create further problems, when in fact many patents help to open up alternative paths through the patent thicket. The elaborate compromises of Hatch-Waxman, which were intended to spur research by strengthening patent protection and then facilitating the turnover to the generic market at patent expiration, represent a sound compromise that should not be dissipated by legislative efforts to undercut the use or duration of existing research patents.
Pharmaceutical Patents in Latin America
Pharmaceutical Patents Benefit Latin American Patients - Council of the Americas, February 2008
Excerpt: Latin America has room for improvement in fostering environments where intellectual property is respected, particularly with regard to patented pharmaceuticals. On many occasions, in fact, countries still reward the copying of patented drugs rather than the development of innovative life-saving medicines. Pharmaceutical innovation, however, is undeniably in the interest of Latin America and its patients, and countries in the region should take concrete steps to create the conditions that foster it, including strong and effective intellectual property protection.
Full Article